Cytosorbents Corp Company Profile (NASDAQ:CTSO)

About Cytosorbents Corp (NASDAQ:CTSO)

Cytosorbents Corp logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTSO
  • CUSIP: N/A
  • Web: www.cytosorbents.com
Capitalization:
  • Market Cap: $122.27 million
  • Outstanding Shares: 28,108,000
Average Prices:
  • 50 Day Moving Avg: $4.61
  • 200 Day Moving Avg: $5.24
  • 52 Week Range: $3.95 - $6.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.83 million
  • Price / Sales: 11.29
  • Book Value: ($0.06) per share
  • Price / Book: -72.50
Profitability:
  • EBIDTA: ($10,770,000.00)
  • Net Margins: -120.04%
  • Return on Equity: -193.13%
  • Return on Assets: -85.97%
Debt:
  • Debt-to-Equity Ratio: 3.26%
  • Current Ratio: 1.81%
  • Quick Ratio: 1.60%
Misc:
  • Average Volume: 166,398 shs.
  • Beta: -0.07
  • Short Ratio: 14.55
 

Frequently Asked Questions for Cytosorbents Corp (NASDAQ:CTSO)

What is Cytosorbents Corp's stock symbol?

Cytosorbents Corp trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents Corp's earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) released its quarterly earnings results on Monday, May, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.06. The business had revenue of $3.11 million for the quarter, compared to analyst estimates of $2.99 million. Cytosorbents Corp had a negative net margin of 120.04% and a negative return on equity of 193.13%. View Cytosorbents Corp's Earnings History.

Where is Cytosorbents Corp's stock going? Where will Cytosorbents Corp's stock price be in 2017?

5 brokers have issued 12 month target prices for Cytosorbents Corp's shares. Their forecasts range from $9.00 to $24.00. On average, they anticipate Cytosorbents Corp's stock price to reach $13.45 in the next twelve months. View Analyst Ratings for Cytosorbents Corp.

What are analysts saying about Cytosorbents Corp stock?

Here are some recent quotes from research analysts about Cytosorbents Corp stock:

  • 1. Maxim Group analysts commented, "CytoSorbents issued a letter to its shareholders today highlighting the progress the company achieved in 2016." (4/19/2017)
  • 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)

Are investors shorting Cytosorbents Corp?

Cytosorbents Corp saw a decline in short interest in the month of March. As of March 31st, there was short interest totalling 759,170 shares, a decline of 2.5% from the March 15th total of 778,803 shares. Based on an average trading volume of 251,285 shares, the days-to-cover ratio is currently 3.0 days.

Who are some of Cytosorbents Corp's key competitors?

Who owns Cytosorbents Corp stock?

Cytosorbents Corp's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.22%), Skylands Capital LLC (1.24%), Sabby Management LLC (0.86%), Geode Capital Management LLC (0.50%), Cowen Group Inc. (0.22%) and California Public Employees Retirement System (0.18%). Company insiders that own Cytosorbents Corp stock include Al Kraus, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents Corp.

Who bought Cytosorbents Corp stock? Who is buying Cytosorbents Corp stock?

Cytosorbents Corp's stock was purchased by a variety of institutional investors in the last quarter, including Skylands Capital LLC, Sabby Management LLC, Cowen Group Inc., Segantii Capital Management Ltd, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Cytosorbents Corp stock in the last two years include Kathleen P Bloch, Michael G Bator and Phillip P Chan. View Insider Buying and Selling for Cytosorbents Corp.

How do I buy Cytosorbents Corp stock?

Shares of Cytosorbents Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cytosorbents Corp stock cost?

One share of Cytosorbents Corp stock can currently be purchased for approximately $4.35.

Analyst Ratings

Consensus Ratings for Cytosorbents Corp (NASDAQ:CTSO) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.45 (209.20% upside)

Analysts' Ratings History for Cytosorbents Corp (NASDAQ:CTSO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Maxim GroupSet Price TargetBuy$10.00MediumView Rating Details
5/15/2017B. RileyReiterated RatingBuy$11.25LowView Rating Details
5/9/2017AegisReiterated RatingBuy$9.00HighView Rating Details
3/6/2017HC WainwrightBoost Price TargetBuy$11.50 -> $13.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
10/29/2015WBB SecuritiesUpgradeSpeculative Buy -> Buy$13.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Cytosorbents Corp (NASDAQ:CTSO)
Earnings by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Earnings History by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytosorbents Corp (NASDAQ:CTSO)
2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.11)($0.11)($0.11)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.08)($0.07)($0.08)
Q4 20172($0.09)($0.08)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytosorbents Corp (NASDAQ:CTSO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cytosorbents Corp (NASDAQ:CTSO)
Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 6.07%
Insider Trades by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Insider Trades by Quarter for Cytosorbents Corp (NASDAQ:CTSO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.00View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.00View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.28View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.00View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.00View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cytosorbents Corp (NASDAQ:CTSO)
Latest Headlines for Cytosorbents Corp (NASDAQ:CTSO)
Source:
DateHeadline
finance.yahoo.com logoCytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference
finance.yahoo.com - May 24 at 12:40 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) PT Set at $10.00 by Maxim Group
www.americanbankingnews.com - May 23 at 8:04 PM
finance.yahoo.com logoETFs with exposure to CytoSorbents Corp. : May 22, 2017
finance.yahoo.com - May 22 at 4:22 PM
finance.yahoo.com logoAferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021
finance.yahoo.com - May 22 at 12:16 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) to Post Q2 2017 Earnings of ($0.07) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 17 at 8:00 AM
americanbankingnews.com logoZacks: Analysts Expect Cytosorbents Corp (CTSO) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - May 16 at 4:04 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Cytosorbents Corp's FY2020 Earnings (CTSO)
www.americanbankingnews.com - May 16 at 1:48 PM
finance.yahoo.com logoCTSO: Revenue Acceleration Expected 2H. REFRESH Efficacy Compelling
finance.yahoo.com - May 16 at 12:11 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Earns "Buy" Rating from B. Riley
www.americanbankingnews.com - May 15 at 7:34 PM
americanbankingnews.com logoCytosorbents Corp to Post Q2 2017 Earnings of ($0.06) Per Share, B. Riley Forecasts (CTSO)
www.americanbankingnews.com - May 11 at 9:26 AM
americanbankingnews.com logoCytosorbents Corp (CTSO) Given "Buy" Rating at B. Riley
www.americanbankingnews.com - May 10 at 9:30 PM
finance.yahoo.com logoCytoSorbents Corp. :CTSO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 4:45 PM
finance.yahoo.com logoETFs with exposure to CytoSorbents Corp. : May 9, 2017
finance.yahoo.com - May 9 at 9:33 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - May 9 at 1:38 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Given "Buy" Rating at Aegis
www.americanbankingnews.com - May 9 at 10:26 AM
finance.yahoo.com logoCytoSorbents Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 9:25 PM
finance.yahoo.com logoCytoSorbents reports 1Q loss
finance.yahoo.com - May 8 at 9:25 PM
finance.yahoo.com logoInvestor Network: CytoSorbents Corporation to Host Earnings Call
finance.yahoo.com - May 8 at 4:25 PM
americanbankingnews.com logoCytosorbents Corp's (CTSO) "Buy" Rating Reiterated at B. Riley
www.americanbankingnews.com - May 6 at 5:08 PM
streetinsider.com logoCytosorbents (CTSO) Presents REFRESH I Trial Results at AATS - StreetInsider.com
www.streetinsider.com - May 5 at 9:48 PM
finance.yahoo.com logoCytoSorbents Announces Positive REFRESH I Trial Results
finance.yahoo.com - May 5 at 4:47 PM
finance.yahoo.com logoCytoSorbents to Report Q1 2017 Operating and Financial Results
finance.yahoo.com - May 2 at 7:57 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Receives Media Sentiment Score of 0.44
www.americanbankingnews.com - May 2 at 12:56 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Earns Coverage Optimism Score of 0.05
www.americanbankingnews.com - April 29 at 2:51 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $2.99 Million
www.americanbankingnews.com - April 27 at 10:24 AM
seekingalpha.com logoBiotech Forum Daily Digest: Biogen Kicks Off Earning Season In Style - Spotlight On Cytosorbents
seekingalpha.com - April 27 at 1:58 AM
americanbankingnews.com logo-$0.11 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter
www.americanbankingnews.com - April 26 at 12:03 AM
americanbankingnews.com logoCytosorbents Corp (CTSO) Receives News Sentiment Rating of 0.28
www.americanbankingnews.com - April 25 at 7:26 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Rating Reiterated by Maxim Group
www.americanbankingnews.com - April 25 at 12:17 PM
streetinsider.com logoCytosorbents (CTSO) Granted $1M Phase II SBIR Contract by U.S. DOD to Advance Fungal Mycotoxin Blood Purification
www.streetinsider.com - April 24 at 4:27 PM
finance.yahoo.com logoCytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification
finance.yahoo.com - April 24 at 9:15 AM
americanbankingnews.com logoCytosorbents Corp (CTSO) Getting Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 20 at 4:54 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - April 19 at 1:14 PM
finance.yahoo.com logoCytoSorbents 2017 - Propelling the Company to the "Next Level"
finance.yahoo.com - April 19 at 12:38 PM
finance.yahoo.com logoCTSO: Equity Raise, Cancer Applications, REFRESH I Data Upcoming
finance.yahoo.com - April 17 at 12:00 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Given News Impact Rating of 0.29
www.americanbankingnews.com - April 13 at 12:08 PM
americanbankingnews.com logoB. Riley Equities Analysts Lift Earnings Estimates for Cytosorbents Corp (CTSO)
www.americanbankingnews.com - April 10 at 7:37 AM
finance.yahoo.com logoETFs with exposure to CytoSorbents Corp. : April 5, 2017
finance.yahoo.com - April 7 at 9:16 AM
americanbankingnews.com logoCytosorbents Corp (CTSO) Earns Buy Rating from B. Riley
www.americanbankingnews.com - April 5 at 11:07 PM
biz.yahoo.com logoCYTOSORBENTS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - April 3 at 10:00 PM
seekingalpha.com logoWatch Out Below In Cytosorbents Corporation: A Reverse Merger Uplisting Running Low On Liquidity
seekingalpha.com - April 1 at 8:53 AM
streetinsider.com logoCytosorbents (CTSO) Prices 2.22M Share Follow-On Offering at $4.50
www.streetinsider.com - March 31 at 4:42 PM
us.rd.yahoo.com logoCytoSorbents Announces Pricing of Follow-On Offering
us.rd.yahoo.com - March 31 at 4:42 PM
finance.yahoo.com logoCytoSorbents Announces Proposed Offering of Common Stock
finance.yahoo.com - March 30 at 5:00 PM
finance.yahoo.com logoCytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia
finance.yahoo.com - March 28 at 12:24 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - March 28 at 9:08 AM
streetinsider.com logoCytosorbents (CTSO) Announces REFRESH I Trial Abstract ... - StreetInsider.com
www.streetinsider.com - March 27 at 4:25 PM
finance.yahoo.com logoCytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
finance.yahoo.com - March 27 at 12:23 PM
finance.yahoo.com logoDr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board
finance.yahoo.com - March 22 at 4:41 PM
americanbankingnews.com logoCytosorbents Corp (CTSO) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - March 22 at 8:13 AM

Social

Chart

Cytosorbents Corp (CTSO) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff